The European Association of Urology (EAU) Renal Cell Cancer Guidelines Panel and the International Kidney Cancer Coalition (IKCC) have issued a joint statement about the rejection of ipilimumab and nivolumab for kidney cancer by the European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP).

The EAU are saying that the CHMP’s decision does not change evidence-based guideline recommendations to offer ipilimumab and nivolumab to patients with intermediate- and poor-risk kidney cancer based on the high level of evidence from the CheckMate 214 randomised trial against the previous standard, sunitinib.

Read the statement in European Urology here